(2S)-2-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-(4-phenyl-2,3-dihydro-1H-inden-1-yloxy)benzylamino)-3-hydroxypropanoic acid

ID: ALA4848279

Chembl Id: CHEMBL4848279

PubChem CID: 134164865

Max Phase: Preclinical

Molecular Formula: C32H28ClN3O5

Molecular Weight: 570.05

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  N#Cc1cncc(COc2cc(OC3CCc4c(-c5ccccc5)cccc43)c(Cl)cc2CN[C@@H](CO)C(=O)O)c1

Standard InChI:  InChI=1S/C32H28ClN3O5/c33-27-12-23(17-36-28(18-37)32(38)39)30(40-19-21-11-20(14-34)15-35-16-21)13-31(27)41-29-10-9-25-24(7-4-8-26(25)29)22-5-2-1-3-6-22/h1-8,11-13,15-16,28-29,36-37H,9-10,17-19H2,(H,38,39)/t28-,29?/m0/s1

Standard InChI Key:  XFMADIVPJSLSMQ-XLTVJXRZSA-N

Alternative Forms

  1. Parent:

    ALA4848279

    ---

Associated Targets(Human)

CD274 Tclin Programmed cell death 1 ligand 1 (299 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDCD1 Tclin Programmed cell death protein 1/Programmed cell death 1 ligand 1 (1367 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 570.05Molecular Weight (Monoisotopic): 569.1717AlogP: 5.45#Rotatable Bonds: 11
Polar Surface Area: 124.70Molecular Species: ACIDHBA: 7HBD: 3
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 0.60CX Basic pKa: 8.15CX LogP: 2.63CX LogD: 2.57
Aromatic Rings: 4Heavy Atoms: 41QED Weighted: 0.22Np Likeness Score: -0.35

References

1. Chen H, Wang K, Yang Y, Huang X, Dai X, Feng Z..  (2021)  Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.,  217  [PMID:33770574] [10.1016/j.ejmech.2021.113377]
2. Huang X, Chen H, Dai X, Xu M, Wang K, Feng Z..  (2021)  Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.,  52  [PMID:34610423] [10.1016/j.bmcl.2021.128403]
3. Zhang J, Zhang Y, Qu B, Yang H, Hu S, Dong X..  (2021)  If small molecules immunotherapy comes, can the prime be far behind?,  218  [PMID:33773287] [10.1016/j.ejmech.2021.113356]

Source